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Introduction
Plasmodium malariae was the first malaria parasite observed in 1881 by Charles Laveran, Nobel Prize winner for discovering the cause of malaria [1] . P. malariae is a cosmopolitan parasite that does not develop below 15˚C and is described in tropical and subtropical regions of sub-Saharan Africa, South America, much of Southeast Asia, Indonesia, and in many islands of the western Pacific. In general, the distribution coincides with that of P. falciparum. In South America, P. malariae is associated with zoonotic infections, and is easily confounded with P. brasilianum, a parasite that infects twelve different genera of New World primates [1] . These and humans have high levels of seropositivity for P. malariae and P. brasilianum antigens in endemic areas [2] .
Parasitemias in P. malariae infections are usually low compared to those in patients infected with P. falciparum or P. vivax perhaps due to its longer developmental cycle (72 h for P. malariae versus 48 h for P. vivax and P. falciparum), lower number of merozoites produced per erythrocyte cycle, and its preference for developing in older erythrocytes [2] . The combination of these factors may be a trigger for the earlier development of an immune response by the host [2] . P. malariae may persist asymptomatically in the infected individual for long periods [3] , but it may also result in sequelae after decades without being perceived by the carrier [4] . Unlike P. vivax and P. ovale infections, there is no evidence of latent liver stage forms (hypnozoites) [2] .
Previous studies point to P. malariae as one of the oldest parasites that cause malaria. The adaptive success is characteristic of the slow biological cycle that favors its survival for long periods in the host organism without being noticed [1] . Although rarely associated with severe malaria, there are cases of nephrotic syndrome related to P. malariae (rev. in [2] ) and cases of death in immunocompromised patients [5, 6] . Also, treatment failures [7, 8] and acute renal injury [9] are attributable to infection caused by P. malariae. It is important to note that this silent survival for long periods in the organism makes this parasite the most important in transfusion malaria [2, 5, 10, 11, 12] . Additionally, is difficult to detect and, consequently, to control. In this sense, an effective vaccine would be a valuable addition to the tools available for malaria control.
Merozoite surface protein 1 (MSP1) is one of the major candidates for an antimalarial vaccine because it is expressed abundantly on the merozoite surface and capable of activating the host protective immunity [13] . Studies using MSP1 in different endemic regions have shown that this protein possesses highly immunogenic fragments that generate an immune response, which frequently associates to protection in natural infections (rev. in [14] ). While many studies that deal with MSP1 from P. vivax and P. falciparum have demonstrated a strong immune response in mice and monkeys [15, 16] , P. malariae MSP1 has not been examined so far.
In order to investigate the immunogenicity of the P. malariae MSP1 polypeptide, we evaluated the humoral and cellular immune responses of BALB/c mice immunized with five recombinant proteins, representing different portions of the PmMSP1 protein.
Materials and methods

PmMSP-1 recombinant proteins
The PmMSP1 fragments were obtained from sample I11, isolated in 2002 from an infected patient in Iporanga, a municipality located in Atlantic Forest Region of the State of São Paulo, Brazil [17] . Five fragments were selected by representing conserved and polymorphic regions of the N-terminal, C terminal and the central portion of the protein (Fig 1A) (modified from [18] ). The positioning of these fragments in relation to the PfMSP1 blocks, where sequences are divided into conserved blocks (white boxes), semi-conserved blocks (hatched boxes), and variable blocks (black boxes) is shown in Fig 1B (modified from [19] ). Primer sequences and amplification conditions used were previously described [18] . The purified fragments were ligated into the pGEM-T Easy vector (Promega) according to the manufacturer's instructions and subsequently subcloned into the pGEX-3Y vector (pGEX-3X altered by fill-in modification of the BamHI site). Recombinant plasmids were checked for their integrity by semiautomatic sequencing using the Big Dye Terminator v3.0 Cycle Sequencing Kit in an ABI Genetic Analyzer 3550 (ABI, USA). The sequences were deposited in GenBank (F1, #KR072279; F2, #KY189271; F3, #KY189272; F4, #KY189273; PmMSP1 19 , #KY189274). The recombinant PvMSP1 19 and PfMSP1 19 proteins corresponding to the amino acid sequence of the 19-kDa fragment of MSP1 of the isolates Belém and S-20, respectively, were used as controls [20, 21] . Then, the expression and purification of all recombinant proteins were performed as previously described [21] . 
Immunization of mice with the recombinant proteins
For all experiments, 6 groups (F1, F2, F3, F4, PmMSP1 19 and GST as control) of four female 6-8 weeks old BALB/c mice were used. The immunization was performed via the intraperitoneal (i.p.) route with 25 μg of recombinant protein in the presence of Freund's incomplete adjuvant (Sigma) and 500 ng monophosphoryl lipid A adjuvant (MPLA) (Avanti)/dose. Three doses were administered at 15-day intervals. Blood samples were collected by a puncture of the submandibular artery of the immunized animals. Blood samples were collected before the first immunization and at the 14th, 28th, 45th and 70th day after the first immunization (Fig 2A) . The blood was incubated at 37˚C for 1 h, then at 4˚C for 1 h and centrifuged at 12,000 rpm for 10 minutes at 4˚C. Resulting serum was separated in new tubes and stored at -20˚C.
ELISA for detection of mouse antibodies against PmMSP1 recombinant proteins
Total IgG antibodies against F1, F2, F3, F4, PmMSP1 19 and GST in mice sera were detected by ELISA 14, 28, 45 and 70 days after the first immunization, as described previously [22] . Recombinant antigens were added to the plates at 250 ng/well and the secondary antibody (peroxidase-coupled goat anti-mouse IgG [KPL]) was used in a 1:5000 dilution. Each serum was analyzed in serial dilutions starting from 1:200. The titers were determined as the highest dilutions presenting optical density (OD) at 450 nm (OD 450 ) values higher than 0.1. These values represent binding of IgG to the recombinant protein after subtraction of binding of the same serum to GST alone. The results are presented as the geometric mean ± standard deviation of four animals per group.
Detection of IgG subclass responses was performed as described above, except that the secondary antibodies were specific for mouse IgG1, IgG2a, IgG2b and IgG3 (all obtained from Bethyl Laboratories) diluted 1:5,000. The OD values of the sera against the fusion proteins were corrected by subtracting the OD values from the GST-coated wells.
The affinities of the antibodies were assessed by a thiocyanate elution-based ELISA [23]. The procedure was similar to that described for the standard ELISA with the inclusion of an extra step. After washing of plates following incubation of the pooled serum dilutions of the sample after the 3rd immunization (1:25,600), ammonium thiocyanate, diluted in PBS, was added to the wells in duplicate, in concentrations ranging from 0 to 8 M. The plates were allowed to stand for 15 min at room temperature before they were washed and incubated with the secondary antibody solution. Afterwards, the concentration of ammonium thiocyanate required to dissociate 50% of the bound antibody was determined. The percentage of binding was calculated as follows: OD 492 in the presence of ammonium thiocyanate x100 / OD 492nm in the absence of ammonium thiocyanate.
Determination of cytokine concentration in spleen cell supernatants
Cytokine levels secreted into the splenocyte culture supernatant stimulated for 72 h with the recombinant proteins (20 μg/mL) or ConA (2.5 μg /mL), were determined using a mouse Th1/ Th2/Th17 cytometric bead array kit (CBA; BD Biosciences) on a LSR Fortessa BD flow cytometer in accordance with manufacturer's instructions and data analysis was performed by FCAP Array v.3 software.
Human serum samples
Serum samples from 15 healthy individuals and 21 individuals with unrelated diseases (3 schistosomiasis, 5 visceral leishmaniasis, 5 Chagas disease, 2 toxoplasmosis, 2 rheumatoid arthritis, 
Immunoblotting assay for PmMSP1 detection
For this analysis, the recombinant proteins were separated by SDS-PAGE (12%) diluted (vol/ vol) in SDS-sample buffer (60 mM Tris-HCl [pH 6.8], 5% 2-mercaptoethanol, 10% glycerol, and 0.01% bromophenol blue), and boiled for 5 min at 100˚C. Samples were loaded on a 12% polyacrylamide minigel (Mini-Protean II; Bio-Rad). Antigens were separated by electrophoresis, transferred to nitrocellulose membranes (Hybond-C, GE Healthcare), and blocked with PBS containing 5% non-fat milk for 1 h at room temperature. Membranes were incubated with a serum pool of P. malariae patients (1:500) diluted in PBS with 1% milk. Bound antibodies were detected with horseradish peroxidase-labeled anti-human IgG (Sigma Co.). The color of detected bands was developed after reaction using a chemiluminescence detection assay (Kit Western Pico Super Signal, Pierce/Thermo Scientific).
Statistical analysis
Statistical analysis was performed using the GraphPad Prism program version 5.0 for Windows (GraphPad Software, USA). For the comparison of antibody titers of more than two groups at the same sampling time ANOVA analysis was used, and a posteriori multiple comparisons between the means of the groups were performed with Tukey's Test. To determine the differences between the sampling times ANOVA double-ranking was used, followed by a Bonferroni test. The cutoffs were established by using the mean plus three standard deviations of signal measured with negative sera.
Ethics statement
The mice used in this study were provided by the Department of Parasitology, Institute of Biomedical Sciences. All the procedures were submitted to the Ethics Committee of the Institute of Medicine Tropical and were approved under the registration number of the Committee on Ethics in the Use of Animals (CEUA) (CPE-IMT / 000304A). All animals immunized were females aged from 4 to 6 weeks and were maintained in a 12 h light/12 h dark cycle with free access to water and standard chow under appropriate environmental and hygienic conditions. Serum was harvested by submandibular vein bleeding. After trials, mice were euthanized using CO 2 asphyxiation as recommended [24] . Ethical clearance for the extension of use of sera from the plasma/sera collection at the Department of Parasitology was obtained before the experimental work (CEPSH protocol 20/2015 and extension No. 1.003.485).
Results
Immunogenicity of five different PmMSP1 recombinant proteins in mice
To characterize the immune responses generated by immunization with PmMSP1, immunogenicity studies in mice were conducted. Groups of 4 BALB/c mice were immunized with F1, F2, F3, F4, PmMSP1 19 and with GST alone as a control, and the resulting antibody responses were measured by ELISA using recombinant proteins. Results in Fig 2B (a-d) show that all the recombinant proteins were immunogenic.
The time course of the immunizations and antibody titers showed that the responses to F1, F2, F3, F4, PmMSP1 19 were boosted after the second immunization while specific antibody titers were similar (1: 809,000) after the third immunization and were maintained until the end of the experiment (day 70) (S1 Fig) (for the Prism files that generate the figures in the paper see Raw Data in S1 File).
The isotype distribution of IgG responses to F1, F2, F3, F4 and PmMSP1 19 showed that all recombinant proteins elicited similar patterns of IgG subclasses. Antibodies of all isotypes were detected with the levels of IgG1, IgG2a and IgG2b higher when compared to IgG3 (Fig  3) . However, no significant differences were observed in the mean OD values between IgG1, IgG2a or IgG2b. The data presented here correspond to pooled sera collected at day 45.
The sera obtained were used to determine their affinity for corresponding recombinant proteins. These antibodies induced after immunization with the recombinant proteins F1, F2, F3 and F4 showed similar affinities since the concentrations of ammonium thiocyanate required for dissociating 50% of the antibodies were similar (1.279 M, 1.087 M, 1.216 M and 1.391 M, respectively). Interestingly, the observed affinity was higher (2.096 M) for PmMSP1 19 (Fig 4) .
Lymphoproliferation assays
The proliferation of lymphocytes stimulated with each antigen was determined by flow cytometry, using CFSE as a proliferation indicator. Concanavalin A stimulation was used to 
Stimulated lymphocytes secrete IL4
After antigenic stimulation, levels of cytokines secreted in the culture supernatants of the splenocytes were determined by CBA (Fig 6) . The levels of Th1/Th2 cytokines detected did not show significant differences when compared between the groups, but we observed that the level of IL-4 in the groups F1 and PmMSP1 19 was higher than in the other groups (Fig 6) . Due to the low levels of cytokines IFN-γ, IL-2, IL-6, IL-10 and TNF-α (Fig 6) found in most animals, differences in these results are not statistically significant.
Patient sera from natural infections recognize PmMSP1 recombinant proteins
The identity and specificity of the recombinant proteins were analyzed by Western blot using a pool of sera from patients positive for P. malariae confirmed by PCR (Fig 7) . The results showed a migration pattern specific and similar in the SDS-PAGE (Fig 7A) . Recombinant proteins of interest, F1, F2, F3, F4, and PmMSP1 19 , reacted with human serum samples of patients was sensitized with PvMSP1 19 (Fig 8, PvMSP1 19 ) or PfMSP1 19 (Fig 8, PfMSP1 19 ), only the sera from patients with P. vivax (C_Pv) or P. falciparum infection (C_Pf) reacted with their corresponding antigens. Some recognition by P. malariae patient sera was also recorded, possibly due to previous, not reported, contact with P. vivax and P. falciparum. Immunogenicity characterization of PmMSP1 recombinant proteins in mice
We also evaluated the reactivity of the recombinant proteins F1, F2, F3 and F4 with those five sera belonging to patients confirmed with P. malariae, P. vivax and P. falciparum by ELISA (Fig 9) . Although our primary goal with this small study was to show the natural antibody response acquired that is induced against the different MSP1 fragments, we found a stronger recognition of F1 (Fig 9, F1) than that obtained for the F2, F3 and F4 recombinant proteins (Fig 9, F2, F3 and F4) . It was also possible to observe a higher recognition of F2 by the homologous serum than by the heterologous sera (Fig 9, F2) .
MSP1 19 from P. malariae was recognized by sera from malaria patients caused by P. malariae (100% of responders, n = 16) (Fig 10) . The corresponding IgGs were species-specific and no reaction was detected with 21 sera from individuals with unrelated diseases (specificity of 100%) (Fig 10) . Cut-off points (OD 0.07) were set at three standard deviations above the mean OD 450 of sera from 15 individuals, never exposed to malarial infection, from the city of São Paulo. The reactivity obtained with the sera of patients from other diseases was similar to that obtained with sera from healthy individuals. This proves that the herein produced PmMSP1 antigens are very useful when a specific humoral response against P. malariae is required.
Discussion
The development of effective methods for malaria diagnosis and control is still on the malaria research agenda. There is currently one vaccine (RTS,S/AS01) being applied in some African countries (https://www.who.int/news-room/detail/23-04-2019-malaria-vaccine-pilotlaunched-in-malawi). Of the 25 malaria vaccine projects under development in the world, four are in stage IIb or III [25, 26] . All but one candidate are targeted exclusively against P. falciparum, which is probably insufficient in areas where a significant proportion of patients suffers from P. vivax or mixed infections. Furthermore, there are three other species that infect humans that have to be considered: P. malariae, P. ovale, and P. knowlesi.
P. malariae has a much lower incidence than P. falciparum and P. vivax, but unlike P. ovale and P. knowlesi, it occurs in all endemic areas of malaria, coexisting with other species, and should, therefore, be considered in the control strategies. In fact, there are no reports to date that study the immune response to P. malariae vaccine candidate antigens. Although the P. malariae merozoite surface protein 1 was isolated and characterized nine years ago [27], this is the first report showing the immunogenicity of five recombinant forms of this protein in BALB/c mice and their recognition by sera from individuals living in malaria-endemic regions of Brazil. Different regions of PmMSP1, covering many parts of the protein, encompassing polymorphic and conserved regions, were fused to glutathione S-transferase (GST). Fusion of GST to the N-terminus of proteins facilitates their purification and often helps to maintain fused polypeptide soluble compared to a 6xHistidine-fusion. The expression system in E. coli was chosen because of its simplicity, cost-effectiveness and high efficiency in the expression of non-glycosylated proteins [28, 29] . The recombinant proteins produced were used to immunize BALB/c mice using monophosphoryl lipid A adjuvant (MPLA) and Freund's incomplete adjuvant. The specificity and subtyping of the antibodies and cellular immune responses were evaluated by ELISA and cytometry, respectively, using the recombinant proteins as antigens.
Immunogenicity of PmMSP1 recombinant proteins in mice
Regarding the response of antibodies against blood stage antigens, known for their importance in protecting against malaria [30], our results demonstrate that the recombinant proteins were immunogenic in mice. The titers of IgG antibodies elicited by F1, F2, F4, and PmMSP1 19 were significantly higher than the antibody titers found in the control group (GST). After the second dose, the most immunogenic proteins were the F1 (N-terminal) and PmMSP1 19 (Cterminal) regions. These regions were also found to be the most immunogenic in other species of Plasmodium, such as P. vivax, where, using recombinant plasmids for the immunization of . It is important to note that IgG2a antibodies from mice are considered the most effective in complement activation and in the activation of antibody-dependent cellular cytotoxic mechanisms, in addition to modulating the parasitemia of P. yoelii [41, 42] . In our study, the recombinant proteins in emulsion with the adjuvant induced a mixed Th1/Th2 response also found in other studies [43] . Different studies have also shown that, in P. yoelii, protection occurs in the presence of elevated levels of IgG1, IgG2a and IgG2b, with a mixed Th1/Th2 immune response [44, 45, 46, 47] .
Cytokines play a critical role in determining the subclasses of IgG. IL-4 is secreted by Th2 cells and is associated with an IgG1 response, an indicator of a predominantly antibody-mediated response. As demonstrated by our results, the spleen cells of the mice immunized and stimulated with F1 and PmMSP1 19 were those with the highest levels of IL-4. IL-10 cytokine is anti-inflammatory, secreted by activated Th2 cells, and is believed to limit harmful inflammatory responses during the blood stage of the parasite in mice [48] . IL-10 was found at a higher level in sera collected from mice immunized with F1 and with PmMSP1 19 . The cytokines produced by each subset promote the polarization, where the cytokines produced by Th1 cells negatively regulate the Th2 response, and vice versa [49] . Therefore, stimulation of Th1/Th2 subsets by immunization with recombinant proteins is important, since homeostasis between Th1/Th2 cells may achieve a balanced regulation between the pro-inflammatory and antiinflammatory actions in the immune response.
Many studies have shown that both cellular and humoral immunity are involved in protective immunity against malaria [39, 50, 51] . Both immune responses were triggered by the recombinant proteins derived from PmMSP1. These results suggest that these fragments of P. malariae may be more widely evaluated as potential vaccine candidates against blood stage parasites. Similar results have been reported in studies involving mice immunized with MSP1 42 recombinant of P. falciparum and P. vivax [36, 37] .
The affinity of an antibody for its corresponding antigen is an important determinant of the antibody's biological efficacy [52, 53] . For bacteria, it has been shown that affinity of antibodies is important for protection from disease after vaccination [54, 55] . More recently, highaffinity antibodies to P. falciparum merozoite antigens were associated with protection from malaria [56] . Thus, we evaluated the sera from the immunized mice for their affinity against the recombinant proteins (F1, F2, F3, F4 , and PmMSP1 19 ) in the presence of the chaotropic agent ammonium thiocyanate. Our results showed that the antibodies generated with immunization with PmMSP1 19 showed the highest affinity, requiring a higher molarity of ammonium thiocyanate to dissociate 50% of the antibodies. In the sera of the animals immunized with the F1, F2, F3 and F4 proteins, the effect of ammonium thiocyanate in the antigen-antibody interaction was very similar. Antibodies with high affinity for the target antigen have also been reported for PvMSP1 19 [57, 58] .
Antigenicity of PmMSP1 recombinant proteins in humans
PmMSP1 recombinant proteins were recognized by IgG antibodies from human sera from patients with malaria caused by P. malariae in western blot assays suggesting that the presence of the GST did not modify the epitopes of MSP1 recognized by human IgG. GST, originally from Schistosoma japonicum, was not recognized by these sera. Our experiments demonstrated that PmMSP1 19 was antigenic in natural infections, with species-specific recognition. Similar results were also found with human sera from Zimbabwe, Haiti, Cambodia and Mozambique, where species-specific reactivity and rare cross-reactivity of host serum to MSP1 19 antigens were demonstrated [59, 60] . Mice immunized with PvMSP1 19 and PfMSP1 19 also showed no reactivity with the respective heterologous antigen [43] . The use of PmMSP1 19 for detection of antibodies in human malaria patients as well as its serological efficacy for detection of IgG and IgM among experimentally infected chimpanzees has also been demonstrated [61] .
Additionally, in our analysis of the reactivity of the F1, F2, F3 and F4 recombinant proteins with sera from positive patients for P. malariae, P. vivax and P. falciparum, we observed that only sera from patients positive for P. malariae recognized the F1 and F2 proteins. This did not occur for F3 and F4, where the observed ODs were generally lower but sera positive for P. vivax and P. falciparum also recognized these proteins. Such cross-reactivity may be a consequence of the higher identity percentage that is observed between these regions and the heterologous proteins (from 50 to 60% at the amino acid level).
By ELISA, we also evaluated recognition of PmMSP1 19 by serum IgG from Brazilian individuals diagnosed with malaria due to P. malariae in parallel with sera from patients with other diseases, reaching 100% of sensitivity and specificity. In the particular case of malaria caused by P. vivax, studies on the naturally acquired humoral immune response against PvMSP1 showed that PvMSP1 19 is the most immunogenic portion of the molecule and is recognized by 90% of the patients in the region of the Brazilian Amazon with a specificity of 98.3% [62, 63] . Studies have also shown that patients from endemic regions have circulating antibodies that specifically recognize the N-terminal region of PvMSP1 [64] . PfMSP1 19 is also strongly recognized by human sera from endemic regions of malaria [65] .
This study represents the first step in assessing humoral and cellular immune responses in animal models, as well as the naturally acquired response to the PmMSP1 antigen. The different recombinant proteins produced here may be useful in sero-epidemiological studies, both in humans as well as non-human primates from different geographic regions, highlighting possible targets in the development of more sensitive and specific diagnostic tests and enabling an evaluation of the exposure to P. malariae or P. brasilianum in populations. Since the produced antigens are quite immunogenic, they may also prove useful for the rational design of vaccine formulations against P. malariae malaria. However, studies as a growth inhibition assay (GIA) and challenges by P. brasilianum of PmMSP1 protein immunized monkeys are still needed to know the true potential of these antigens as vaccine candidates. 
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